These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35061101)

  • 1. Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
    Rai A; Connelly KA; Verma S; Mazer CD; Teoh H; Ng MY; Roifman I; Quan A; Pourafkari M; Jimenez-Juan L; Ramanan V; Ge Y; Deva DP; Yan AT
    Acta Diabetol; 2022 Apr; 59(4):575-578. PubMed ID: 35061101
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Bami K; Gandhi S; Leong-Poi H; Yan AT; Ho E; Zahrani M; Garg V; Zuo F; Teoh H; Quan A; Leiter LA; Gilbert RE; Zinman B; Thorpe KE; Jüni P; Mazer CD; Verma S; Ong G; Connelly KA
    J Am Soc Echocardiogr; 2020 May; 33(5):644-646. PubMed ID: 32199780
    [No Abstract]   [Full Text] [Related]  

  • 4. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
    Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
    Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
    BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
    Lan NSR; Yeap BB; Fegan PG; Green G; Rankin JM; Dwivedi G
    Int J Cardiovasc Imaging; 2021 Feb; 37(2):517-527. PubMed ID: 32959096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter by Tsuda Regarding Article, "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial".
    Tsuda K
    Circulation; 2020 Mar; 141(9):e100-e101. PubMed ID: 32119586
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
    Natali A; Nesti L; Fabiani I; Calogero E; Di Bello V
    Cardiovasc Diabetol; 2017 Oct; 16(1):130. PubMed ID: 29025406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
    Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
    Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
    Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
    Mason T; Coelho-Filho OR; Verma S; Chowdhury B; Zuo F; Quan A; Thorpe KE; Bonneau C; Teoh H; Gilbert RE; Leiter LA; Jüni P; Zinman B; Jerosch-Herold M; Mazer CD; Yan AT; Connelly KA
    JACC Cardiovasc Imaging; 2021 Jun; 14(6):1164-1173. PubMed ID: 33454272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Mazer CD; Hare GMT; Connelly PW; Gilbert RE; Shehata N; Quan A; Teoh H; Leiter LA; Zinman B; Jüni P; Zuo F; Mistry N; Thorpe KE; Goldenberg RM; Yan AT; Connelly KA; Verma S
    Circulation; 2020 Feb; 141(8):704-707. PubMed ID: 31707794
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute benefits of empagliflozin in type 2 diabetes: a game changer?
    Kumana CR; Tan KCB; Cheung BMY
    Postgrad Med J; 2017 Jul; 93(1101):373-375. PubMed ID: 28433975
    [No Abstract]   [Full Text] [Related]  

  • 15. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
    Hess DA; Terenzi DC; Trac JZ; Quan A; Mason T; Al-Omran M; Bhatt DL; Dhingra N; Rotstein OD; Leiter LA; Zinman B; Sabongui S; Yan AT; Teoh H; Mazer CD; Connelly KA; Verma S
    Cell Metab; 2019 Oct; 30(4):609-613. PubMed ID: 31477497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.